Papers for
pharmaceutical analytics teams
Papers whose findings have a practical use for this group, as judged from the abstract. Open a paper to read what it means in practice.
ProCARE improves automation of real-world health studies with profile-based contracts
ProCARE: Real-World Study Automation via Profile-Grounded Evidence Contracts
Abstract: Real-world studies (RWS) analyze routinely collected healthcare data, such as electronic health records and insurance claims, to estimate treatment effects, monitor safety, and identify risk factors outside randomized trials. Automating RWS with large language model agents is appealing but brittle: valid analyses depend on dataset-specific clinical semantics, including index dates, follow-up windows, patient/event-level units, and outcome boundaries that are often implicit in observational data. This leads to schema mismatches, temporal errors, inconsistent analytical granularity, and unsupported clinical claims. We present ProCARE, a profile-grounded framework that reformulates RWS automation as constrained compilation. ProCARE converts heterogeneous data profiles into Evidence Contracts specifying available variables, temporal attributes, distributions, and evidentiary limits, and compiles study objectives into RWS-IR, a strongly typed intermediate representation for variables, time relations, analysis units, and statistical tasks. Deterministic validation and localized repair then check and revise generated workflows across schema mapping, cohort construction, variable derivation, analysis, and interpretation. On 36 EHR-based benchmark tasks, ProCARE outperforms strong LLM-agent baselines in code executability, semantic consistency, and conclusion traceability, with automated violation diagnoses showing moderate-to-substantial agreement with blinded expert review.
Model predicts continuous patient health changes using clinical history
Learning Continuous Patient Trajectories from Electronic Health Records
Abstract: Electronic health records provide irregular observations of latent patient states that evolve continuously over time. Recent autoregressive models condition on clinical histories to forecast future events as sequences of discrete observations. Conversely, multi-marginal flow matching provides a continuous-time formulation, but using multiple observations to supervise training paths does not itself give the learned dynamics access to preceding patient history. We introduce EHRFlow, a multi-marginal flow-matching framework that conditions on encoded patient history, thereby allowing future dynamics to depend on the patient's prior clinical trajectory. Our proposed framework accommodates irregular observation times and supports forecasting at arbitrary horizons. Across controlled synthetic benchmarks, EHRFlow improves clinical-code forecasting and latent-state recovery. On real-world clinical datasets comprising more than one million patients, including an independent external validation cohort, EHRFlow improves horizon-averaged top-5 clinical-code accuracy over autoregressive and history-independent flow-matching baselines. Finally, in a controlled counterfactual simulation, conditional guidance approximates the known effect of an antihypertensive intervention without training a task-specific outcome model.
BioDyad synchronizes biomedical discovery and machine learning engineering
BioDyad: Synchronize Biomedical Discovery and Machine Learning Engineering
Abstract: Agentic biomedical machine learning (ML) draws on complementary advances in biomedical evidence acquisition and executable program search. Existing systems connect aspects of these capabilities, but coordinating them throughout program search remains challenging. New evidence must guide candidate construction, execution outcomes must inform subsequent discovery and reuse, and validation demands must fit the search budget. We introduce BioDyad, which couples biomedical discovery and ML engineering through two hierarchies within Monte Carlo graph search. Its scientific hierarchy combines prior biomedical guidance with iterative discovery, then links biomedical plans to execution outcomes in memory for reuse across candidates. Its engineering hierarchy moves candidate programs from smoke execution, through train/validation evaluation, to full-data retraining. We evaluate BioDyad on the 76-task BioXArena benchmark under a two-hour per-task budget with three matched LLM backends. It achieves the highest penalized all-task score and task success rate among four agent methods and a one-shot baseline under each backend. These results support coordinating biomedical discovery and ML engineering to integrate external knowledge into executable programs across heterogeneous biomedical tasks.